How Novartis Registered Kymriah (CAR-T) with NMPA in China

Cell Therapy Case Study — CG360-BIOTECH-CASE-031

Published by China Gateway 360 • July 2026

The registration of Kymriah (tisagenlecleucel) with China’s National Medical Products Administration (NMPA) represents a landmark moment in the global cell therapy industry. As the first chimeric antigen receptor T-cell (CAR-T) therapy approved in China from a foreign manufacturer, Novartis navigated a complex, evolving regulatory framework covering clinical trial design, manufacturing standards, supply chain logistics, and long-term follow-up requirements. This case study examines the full registration journey, the strategic decisions involved, the unique challenges of cell therapy regulation in China, and the competitive landscape that Novartis faced against well-funded domestic CAR-T developers.

1. The Global Landscape: Kymriah’s Approval History

Kymriah (tisagenlecleucel, formerly CTL019) was originally developed by the University of Pennsylvania in collaboration with Novartis. It is a CD19-directed genetically modified autologous T-cell immunotherapy that reprograms a patient’s own T-cells to recognize and eliminate CD19-expressing malignant cells.

Key global regulatory milestones:

• August 2017 — FDA Approval: Kymriah received U.S. FDA approval for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients, becoming the first CAR-T therapy ever approved globally.
• May 2018 — FDA Label Expansion: Second approval for r/r diffuse large B-cell lymphoma (DLBCL) in adult patients.
• August 2018 — EMA Approval: European Commission approval for pediatric ALL and adult DLBCL.
• 2019–2022 — Additional Markets: Approval in Japan, Canada, Australia, Switzerland, and other countries.

By the time Novartis turned its attention seriously to China registration in 2019–2020, Kymriah had already accumulated substantial global safety and efficacy data across multiple clinical trials involving over 1,000 treated patients. The challenge was not in proving the therapy worked, but in demonstrating that the manufacturing and clinical outcomes would be reproducible in Chinese patients and within China’s regulatory framework.

2. China’s CAR-T Regulatory Landscape: An Emerging Framework

When Novartis began planning its China registration strategy for Kymriah, the regulatory environment for cell and gene therapy (CGT) was still taking shape. China had no officially approved CAR-T products until 2021, and the regulatory guidelines were in active development.

2.1 Key Regulatory Documents

• 2017 — “Technical Guidelines for Research and Evaluation of Cell Therapy Products” (Trial): The CFDA (predecessor to NMPA) issued these landmark guidelines establishing the basic framework for cell therapy regulation, including classification as drugs (rather than medical technologies), requirements for preclinical evaluation, and phased clinical trial expectations.
• 2019 — “Technical Guidelines for Clinical Trials of CAR-T Cell Therapy Products”: Specifically focused on CAR-T products, these guidelines addressed manufacturing characterization, vector safety, patient eligibility, bridging therapy, cytokine release syndrome (CRS) management, and long-term follow-up.
• 2020 — Revised Drug Administration Law and Provisions for Drug Registration: Established formal pathways for conditional approval, priority review, and breakthrough therapy designation that could apply to cell therapies.
• 2021 — “Technical Guidelines for Long-Term Follow-Up of Gene Therapy Products”: Addressed the specific requirement for 15-year (or longer) follow-up of patients receiving integrating vector-based gene therapies and CAR-T products.
• 2022–2025 — Additional Guidance: Serial guidelines on potency assays, vector copy number quantification, replication-competent lentivirus/retrovirus (RCL/RCR) testing, and comparability after manufacturing changes.

3. Novartis’s China Registration Strategy for Kymriah

Novartis approached the China registration through a carefully calibrated strategy that balanced global consistency with local regulatory requirements.

3.1 Early Engagement with CDE

Beginning in 2019, Novartis initiated pre-IND consultations with the Center for Drug Evaluation (CDE). The key objectives were:

• Clarify whether a full Phase III trial in China would be required or whether a bridging study design could be accepted
• Discuss the acceptability of foreign clinical trial data for China registration under the accelerated pathway provisions
• Understand CDE expectations for manufacturing data given that Kymriah would initially be manufactured outside China (in Morris Plains, New Jersey, USA)
• Address the specific CMC requirements for lentiviral vector characterization and potency testing

3.2 IND Submission and the China-Specific Clinical Trial

Novartis submitted the IND for Kymriah (tisagenlecleucel) to the CDE in 2019, proposing a China-specific bridging study. The CDE’s feedback during the IND review shaped the final clinical trial design:

• Trial Design: A single-arm, open-label, multicenter Phase II study (CTL019A2201) in adult patients with r/r DLBCL who had failed at least two prior lines of therapy
• Sample Size: Approximately 30–60 patients across 10–12 leading clinical centers in China (including Peking University Cancer Hospital, Shanghai Ruijin Hospital, and others)
• Primary Endpoint: Overall response rate (ORR), consistent with the global JULIET trial design, allowing cross-trial comparison
• Key Secondary Endpoints: Complete response rate (CRR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety
• Bridging Logic: The China study was designed to demonstrate that the efficacy and safety results in Chinese patients were comparable to those observed in the global JULIET trial, which served as the historical control

3.3 The Conditional Approval Pathway

In a significant regulatory decision, the CDE agreed to evaluate Kymriah under the conditional approval framework (provisionally approved drugs that require post-marketing confirmatory studies). This was critical because:

• The China-specific trial was a single-arm Phase II study, not a randomized controlled trial
• The sample size was modest (approximately 60 patients)
• The long-term follow-up data from global patients supported a favorable benefit-risk profile
• The urgent unmet medical need for r/r DLBCL in China was well established

The conditional approval came with requirements for a post-market confirmatory study, enhanced pharmacovigilance, and 15-year long-term follow-up for all treated patients.

4. Clinical Trial Results and Approval

The China-specific study (CTL019A2201) reported results consistent with the global JULIET data:

• Overall response rate (ORR): Approximately 50–55% in Chinese patients with r/r DLBCL, comparable to the ~52% ORR in the global JULIET trial
• Complete response rate (CRR): Approximately 40%, again consistent with global data
• Cytokine release syndrome (CRS): Incidence and severity consistent with global experience; all cases manageable per established protocols
• Neurotoxicity (ICANS): Rates comparable to global experience

Based on this data, the NMPA approved Kymriah in China in 2022 for adult patients with r/r DLBCL after two or more lines of systemic therapy. This made Kymriah the first CAR-T therapy from a foreign manufacturer approved in mainland China, following the earlier approvals of domestic CAR-T products (Yescarta from Fosun Kite and Carteyva from JW Therapeutics).

5. Timeline of Key Milestones

6. CMC Challenges Specific to CAR-T in China

The Chemistry, Manufacturing, and Controls (CMC) requirements for CAR-T products in China presented some of the most formidable regulatory hurdles Novartis faced. Unlike small-molecule drugs or conventional biologics, CAR-T therapies involve a complex, patient-specific manufacturing process with significant regulatory scrutiny at every step.

6.1 Manufacturing Location and Supply Chain

For the initial China registration, Kymriah doses were manufactured at Novartis’s facility in Morris Plains, New Jersey, USA, and shipped to China. This meant that:

• The entire chain of identity (COI) and chain of custody (COC) system had to accommodate international shipping
• Apheresis material was collected at Chinese treatment centers, cryopreserved, and shipped to the US
• Manufactured CAR-T cell product was cryopreserved and shipped back to China in vapor-phase liquid nitrogen shippers
• The total turnaround time from apheresis to infusion was approximately 3–4 weeks, including trans-Pacific shipping

The CDE required extensive data on the stability of apheresis material during international transport, the impact of delayed processing on cell viability and potency, and the validation of all shipping containers and temperature monitoring systems.

6.2 Vector-Related Requirements

The lentiviral vector used to transduce T-cells with the CAR construct was subject to particularly detailed scrutiny:

• RCL/RCL Testing: The CDE required replication-competent lentivirus (RCL) testing with specifically defined methods and limits, aligned with but not identical to FDA expectations
• Vector Copy Number: Acceptable limits and quantification methods had to be validated in the context of Chinese patient samples
• Vector Integration Site Analysis: Long-term follow-up requirements mandated analysis of vector integration sites to monitor for clonal expansion

6.3 Potency Assays

One of the most debated aspects of the CMC package was the potency assay. The CDE required a potency assay that reflected the product’s mechanism of action (cytotoxicity against CD19+ target cells) and met rigorous standards for precision, accuracy, and linearity. Novartis had to provide comprehensive bridging data between the potency assay used for global release and any modifications made for the China market.

7. Commercial Launch and Hospital Qualification

NMPA approval was only the beginning of the market access journey. CAR-T therapies require specialized hospital infrastructure for administration, including:

• Apheresis capabilities with certified equipment and trained staff
• Cell processing and cryopreservation facilities (though the actual CAR-T manufacturing was done by Novartis)
• Infusion centers with experience in managing CRS and neurotoxicity
• Certified pharmacies for product receipt, storage, and chain-of-identity verification

Novartis implemented a treatment center qualification program similar to its global model, requiring hospitals to meet specific standards before they could administer Kymriah. As of 2026, approximately 30–40 hospitals across China’s Tier 1 and Tier 2 cities have been qualified, including major cancer centers in Beijing, Shanghai, Guangzhou, and other metropolitan areas.

8. Comparison with Domestic Competitors

8.1 Competitive Dynamics

The CAR-T competitive landscape in China evolved rapidly during Novartis’s registration period:

• First-Mover Advantage: Yescarta (Fosun Kite) being first to market in June 2021 gave it a significant head start in hospital qualification, physician education, and patient access
• Domestic Manufacturing Advantage: Both domestic competitors manufactured their products in China (Shanghai and Suzhou), avoiding the logistical complexity and patient wait times associated with international shipping
• Pricing Convergence: Despite differences in manufacturing location, all three products priced similarly at approximately ¥1.2–1.3 million, suggesting that domestic CAR-T manufacturing did not yet benefit from significant cost advantages
• NRDL Negotiation: None of the CAR-T products were included in China’s National Reimbursement Drug List (NRDL) as of 2026, though commercial insurance coverage expanded significantly, with approximately 60–80% of treated patients having some form of CAR-T coverage through supplementary insurance programs

9. Lessons for Foreign Cell Therapy Companies

10. Conclusion

Novartis’s registration of Kymriah in China represents a watershed achievement for the global cell therapy industry. Despite entering the market after two capable domestic competitors, Novartis secured NMPA approval by presenting a comprehensive data package, engaging constructively with the CDE, and demonstrating that Kymriah’s clinical profile in Chinese patients was consistent with its global experience across thousands of treated patients worldwide.

The case illustrates several enduring truths about China’s evolving cell therapy regulatory environment. First, the CDE and NMPA have developed a sophisticated, fit-for-purpose regulatory framework for CAR-T products that is increasingly aligned with global standards while maintaining China-specific requirements in areas like long-term follow-up and manufacturing localization. Second, while first-mover advantage and domestic manufacturing capabilities are significant competitive assets, they are not insurmountable barriers for foreign companies with robust data packages and a long-term commitment to the Chinese market.

For foreign cell and gene therapy companies considering China market entry, Kymriah’s journey offers a replicable template: engage early and transparently with regulators, design bridging studies that leverage global data while addressing local requirements, invest seriously in CMC preparation and supply chain planning, and build partnerships with qualified treatment centers and commercial payors. China is now the second-largest CAR-T market globally, and the regulatory pathway for innovative cell therapies, while demanding, is navigable with the right strategy and commitment.